R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular designed Magnitude for treating below-the-knee (BTK) peripheral arterial disease (PAD). With the FDA granting IDE, it can now initiate the ELITE-BTK pivotal trial for the next-generation bioresorbable scaffold. R3 Vascular makes […]
R3 Vascular
Bioresorbable scaffold maker R3 Vascular raises $87M, names new CEO
R3 Vascular announced today that it closed an $87 million Series B financing round and appointed Christopher Owens as president and CEO. Owens succeeds founder Kamal Ramzipoor, who intends to transition to the role of chief technology officer (CTO). Mountain View, California-based R3 develops bioresorbable scaffolds for treating peripheral arterial disease (PAD). The company makes […]
